RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
E-Therapeutics Stock

E-Therapeutics Dividend 2025

E-Therapeutics Dividend

0 GBP

E-Therapeutics Dividend yield

Ticker

ETX.L

ISIN

GB00B2823H99

WKN

A0M8VQ

How much dividend does E-Therapeutics 2025 pay?

According to the latest status from July 2025, E-Therapeutics paid a total of 0 GBP per share in dividends within the last 12 months. With the current E-Therapeutics price of 0.09 GBP, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical E-Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the E-Therapeutics Dividend Safe?

E-Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, E-Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding E-Therapeutics's Dividend Distributions

E-Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining E-Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

E-Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in E-Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

E-Therapeutics Aktienanalyse

What does E-Therapeutics do?

E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It was founded in 2003 by Prof. Malcolm Young and has made significant progress in the field of drug development since then. The company has always aimed for an innovative business model focused on identifying new compounds through computer simulations. E-Therapeutics has developed a unique platform called Network Pharmacology, which simulates complex biological systems and identifies potential drug candidates. The platform uses mathematical models and artificial intelligence to identify molecules that can have a positive effect on specific cells. E-Therapeutics' business model is designed to collaborate with partners in developing new drug candidates. The company offers its platform and expertise to support customers in identifying new chemical compounds. E-Therapeutics works closely with top pharmaceutical companies to advance the development of new drugs. E-Therapeutics is divided into three divisions, each focusing on different areas of medical drug research: 1. Oncology division: This division focuses on developing drugs for the treatment of cancer. E-Therapeutics uses its unique platform to develop targeted therapies tailored to the individual needs of the patient. The platform can also be used to identify new biomarkers and potential therapeutics for a variety of cancer diseases. 2. Neurology division: E-Therapeutics' neurology division focuses on identifying drugs for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and Huntington's. E-Therapeutics' platform has already been used to identify new drug candidates that could have a positive effect on the symptoms of these diseases. 3. Infectious Diseases division: E-Therapeutics' infectious diseases division focuses on the development of drugs for the treatment of infectious diseases such as HIV and influenza. E-Therapeutics uses its platform to identify new compounds that have the potential to fight infections and prevent the spread of diseases. E-Therapeutics has a pipeline of products targeting different medical fields. One promising product is ETS-101, a novel drug candidate for the treatment of pain. ETS-101 has already shown positive results in preclinical studies and is currently in phase 1 studies. Another promising product is ETS-6103, being developed for the treatment of depression. ETS-6103 has been successfully tested in preclinical studies and is currently in phase 2 clinical development. In summary, E-Therapeutics focuses on developing drugs that work at a biological level. The company's innovative business model, unique platform, and collaboration with top pharmaceutical companies make it a key player in medical drug research. With a pipeline of promising products, E-Therapeutics has the potential to change the face of medical drug research and advance the world of medicine. Answer: E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It focuses on identifying new compounds through computer simulations and has developed a unique platform called Network Pharmacology. The company collaborates with partners to develop new drug candidates and is divided into divisions focused on oncology, neurology, and infectious diseases. E-Therapeutics has a pipeline of promising products, including ETS-101 for pain treatment and ETS-6103 for depression treatment. It aims to advance medical drug research and contribute to the field of medicine. E-Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about E-Therapeutics stock

How much dividend does E-Therapeutics pay?

Over the past 12 months, E-Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, E-Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of E-Therapeutics?

The current dividend yield of E-Therapeutics is .

When does E-Therapeutics pay dividends?

E-Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of E-Therapeutics?

E-Therapeutics paid dividends every year for the past 0 years.

What is the dividend of E-Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is E-Therapeutics located?

E-Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von E-Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of E-Therapeutics from 7/15/2025 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 7/15/2025.

When did E-Therapeutics pay the last dividend?

The last dividend was paid out on 7/15/2025.

What was the dividend of E-Therapeutics in the year 2024?

In the year 2024, E-Therapeutics distributed 0 GBP as dividends.

In which currency does E-Therapeutics pay out the dividend?

The dividends of E-Therapeutics are distributed in GBP.

Andere Kennzahlen von E-Therapeutics

Our stock analysis for E-Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of E-Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.